Disclaimer: "On April 23, 2024, the FDA granted accelerated approval to tovorafenib (Ojemda) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation."
Login to view comments.
Click here to Login
